S
Stephen D. Nimer
Researcher at University of Miami
Publications - 335
Citations - 22694
Stephen D. Nimer is an academic researcher from University of Miami. The author has contributed to research in topics: Haematopoiesis & Leukemia. The author has an hindex of 77, co-authored 324 publications receiving 20708 citations. Previous affiliations of Stephen D. Nimer include Memorial Hospital of South Bend & Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson,Peter L. Greenberg,John M. Bennett,Bob Löwenberg,Pierre W. Wijermans,Stephen D. Nimer,Antonio Pinto,Miloslav Beran,Theo de Witte,Richard Stone,Moshe Mittelman,Guillermo Sanz,Steven D. Gore,Charles A. Schiffer,Hagop M. Kantarjian +14 more
TL;DR: Recommendations for revisions of some of the initial response criteria for evaluating clinically significant responses in myelodysplastic syndromes are presented.
Journal ArticleDOI
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.
Kelly Moran-Crusio,Linsey Reavie,Alan Shih,Omar Abdel-Wahab,Delphine Ndiaye-Lobry,Camille Lobry,Maria E. Figueroa,Aparna Vasanthakumar,Jay P. Patel,Xinyang Zhao,Fabiana Perna,Suveg Pandey,Jozef Madzo,Chun-Xiao Song,Qing Dai,Chuan He,Sherif Ibrahim,Miloslav Beran,Jiri Zavadil,Stephen D. Nimer,Stephen D. Nimer,Ari Melnick,Lucy A. Godley,Iannis Aifantis,Ross L. Levine +24 more
TL;DR: An animal model of conditional Tet2 loss in the hematopoietic compartment that leads to increased stem cell self-renewal in vivo as assessed by competitive transplant assays is reported.
Journal ArticleDOI
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
Richard Stone,Daniel J. DeAngelo,Virginia M. Klimek,Ilene Galinsky,Eli Estey,Stephen D. Nimer,Wilson Grandin,David Lebwohl,Yanfeng Wang,Pamela S. Cohen,Edward A. Fox,Donna Neuberg,Jennifer J. Clark,D. Gary Gilliland,James D. Griffin +14 more
TL;DR: KC412 is an oral tyrosine kinase inhibitor with clinical activity in patients with AML whose blasts have an activating mutation of FLT3, suggesting potential use in combination with active agents, such as chemotherapy.
Journal ArticleDOI
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.
Omar Abdel-Wahab,Mazhar Adli,Lindsay M. LaFave,Jie Gao,Todd Hricik,Alan H. Shih,Suveg Pandey,Jay P. Patel,Young Rock Chung,Richard Koche,Fabiana Perna,Xinyang Zhao,Jordan E. Taylor,Christopher Y. Park,Martin Carroll,Ari Melnick,Stephen D. Nimer,Jacob D. Jaffe,Iannis Aifantis,Bradley E. Bernstein,Ross L. Levine,Ross L. Levine +21 more
TL;DR: It is identified that ASXL1 mutations result in loss of polycomb repressive complex 2 (PRC2)-mediated histone H3 lysine 27 (H3K27) tri-methylation, and that loss of AS XL1 in vivo collaborates with NRASG12D to promote myeloid leukemogenesis.
Journal ArticleDOI
p53 Regulates Hematopoietic Stem Cell Quiescence
Yan Liu,Shannon Elf,Yasuhiko Miyata,Goro Sashida,Yuhui Liu,Gang Huang,Silvana Di Giandomenico,Jennifer May Lee,Anthony DeBlasio,Silvia Menendez,Jack Antipin,Boris Reva,Andrew Koff,Stephen D. Nimer +13 more
TL;DR: A critical role of p53 is defined in regulating hematopoietic stem cell quiescence, especially in promoting the enhanced quiescent seen in HSCs that lack the MEF/ELF4 transcription factor.